Total Payments
$40,030
2024 Payments
$4,099
Companies
50
Transactions
1,002
Medicare Patients
2,173
Medicare Billing
$254,796
Payment Breakdown by Category
Food & Beverage$19,691 (49.2%)
Other$11,800 (29.5%)
Travel$4,672 (11.7%)
Consulting$3,850 (9.6%)
Education$16.74 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $19,691 | 975 | 49.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $6,000 | 2 | 15.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,800 | 6 | 14.5% |
| Travel and Lodging | $4,672 | 15 | 11.7% |
| Consulting Fee | $3,850 | 1 | 9.6% |
| Education | $16.74 | 1 | 0.0% |
| Unspecified | $0 | 2 | 0.0% |
Payments by Type
General
$40,030
1,000 transactions
Ownership
$0
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $8,873 | 60 | $0 (2020) |
| Valeant Pharmaceuticals North America LLC | $7,951 | 25 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $4,144 | 3 | $0 (2023) |
| ABBVIE INC. | $3,637 | 186 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $2,642 | 169 | $0 (2024) |
| Celgene Corporation | $2,029 | 73 | $0 (2024) |
| Janssen Biotech, Inc. | $1,260 | 49 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,127 | 62 | $0 (2024) |
| PFIZER INC. | $1,105 | 58 | $0 (2024) |
| QOL Medical, LLC | $867.17 | 47 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,099 | 173 | ABBVIE INC. ($490.82) |
| 2023 | $3,582 | 182 | AbbVie Inc. ($697.51) |
| 2022 | $7,665 | 139 | E.R. Squibb & Sons, L.L.C. ($4,030) |
| 2021 | $1,499 | 94 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($572.92) |
| 2020 | $872.39 | 54 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($229.42) |
| 2019 | $1,690 | 84 | AbbVie, Inc. ($527.56) |
| 2018 | $3,072 | 138 | Wilson Cook Medical Incorporated ($741.00) |
| 2017 | $17,551 | 138 | Allergan Inc. ($8,147) |
All Payment Transactions
1,002 individual payment records from CMS Open Payments — Page 1 of 41
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $18.11 | General |
| Category: Gastroenterology | ||||||
| 12/19/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $27.51 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $22.34 | General |
| Category: Gastroenterology | ||||||
| 12/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $12.72 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/16/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $42.61 | General |
| Category: THERAPY FOR CSID | ||||||
| 12/13/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $4.83 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 12/12/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $24.39 | General |
| Category: LIVER DISEASE | ||||||
| 12/11/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $124.90 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $25.07 | General |
| Category: Immunology | ||||||
| 12/10/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $15.49 | General |
| Category: THERAPY FOR CSID | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $20.97 | General |
| Category: Immunology | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $4.49 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $24.70 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: Gastroenterology | ||||||
| 12/04/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: Immunology | ||||||
| 11/27/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $22.61 | General |
| Category: Rare Disease | ||||||
| 11/27/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $0.72 | General |
| Category: Rare Disease | ||||||
| 11/25/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $19.20 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $27.09 | General |
| Category: Immunology | ||||||
| 11/21/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $26.29 | General |
| Category: THERAPY FOR CSID | ||||||
| 11/18/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $27.83 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/13/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $4.30 | General |
| Category: Gastroenterology | ||||||
| 11/07/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $23.46 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $24.46 | General |
| Category: Immunology | ||||||
| 11/05/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 442 | 513 | $267,655 | $53,648 |
| 2022 | 12 | 497 | 585 | $302,395 | $58,557 |
| 2021 | 12 | 626 | 753 | $414,409 | $74,205 |
| 2020 | 14 | 608 | 767 | $404,838 | $68,385 |
Total Patients
2,173
Total Services
2,618
Medicare Billing
$254,796
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 131 | 174 | $44,022 | $17,405 | 39.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 85 | 90 | $73,755 | $8,152 | 11.1% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 34 | 34 | $49,256 | $7,341 | 14.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 46 | 46 | $54,142 | $6,038 | 11.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 58 | 75 | $14,025 | $4,852 | 34.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 35 | 35 | $8,663 | $2,769 | 32.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $5,891 | $2,417 | 41.0% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 11 | 11 | $11,435 | $2,136 | 18.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 20 | $3,080 | $1,333 | 43.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $3,388 | $1,206 | 35.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 122 | 183 | $29,756 | $12,411 | 41.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 77 | 90 | $21,666 | $9,056 | 41.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 81 | 85 | $103,002 | $7,664 | 7.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 22 | 22 | $33,981 | $4,792 | 14.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 33 | 33 | $44,763 | $4,501 | 10.1% |
| 43242 | Ultrasound guided needle aspiration or biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 18 | 19 | $16,905 | $4,310 | 25.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 29 | 29 | $6,954 | $3,334 | 47.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 42 | 51 | $6,489 | $3,087 | 47.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 22 | 22 | $7,002 | $3,042 | 43.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 29 | 29 | $6,178 | $2,248 | 36.4% |
| 43238 | Ultrasound guided needle aspiration or biopsy of esophagus using a flexible endoscope | Facility | 2022 | 11 | 11 | $10,588 | $2,172 | 20.5% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 11 | 11 | $15,113 | $1,940 | 12.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 144 | 207 | $28,980 | $15,082 | 52.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 82 | 102 | $23,460 | $11,141 | 47.5% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 110 | 115 | $172,500 | $10,841 | 6.3% |
About Eddy Castillo
Eddy Castillo is a Specialist healthcare provider based in Fairfield, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/17/2005. The National Provider Identifier (NPI) number assigned to this provider is 1225020134.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Eddy Castillo has received a total of $40,030 in payments from pharmaceutical and medical device companies, with $4,099 received in 2024. These payments were reported across 1,002 transactions from 50 companies. The most common payment nature is "Food and Beverage" ($19,691).
As a Medicare-enrolled provider, Castillo has provided services to 2,173 Medicare beneficiaries, totaling 2,618 services with total Medicare billing of $254,796. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Fairfield, CT
- Active Since 08/17/2005
- Last Updated 10/30/2007
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1225020134
Products in Payments
- LINZESS (Drug) $6,267
- XIFAXAN (Drug) $6,140
- UCERIS (Drug) $3,365
- VIBERZI (Drug) $3,193
- ZEPOSIA (Drug) $2,013
- XELJANZ (Drug) $1,105
- Humira (Biological) $852.76
- TRULANCE (Drug) $779.42
- RINVOQ (Biological) $719.57
- STELARA (Biological) $585.68
- ENTYVIO (Biological) $579.89
- ZENPEP (Drug) $545.47
- REMICADE (Biological) $530.99
- IBSRELA (Drug) $514.85
- Sucraid (Drug) $477.54
- DUPIXENT (Biological) $425.50
- SUCRAID (Drug) $389.63
- SKYRIZI (Biological) $381.92
- Linzess (Drug) $374.80
- VOQUEZNA (Drug) $352.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Fairfield
Dr. Julie Spivack, Md, MD
Specialist — Payments: $13,443
Specialist $13,443
Dr. Strick Woods
Specialist — Payments: $11,734
Specialist $11,734
Dr. Emil Blanco, Md, MD
Specialist — Payments: $11,406
Specialist $11,406
Dr. Edward Pinto, Md, MD
Specialist — Payments: $9,438
Specialist $9,438
Dr. Gena Cobrin, Md, MD
Specialist — Payments: $8,930
Specialist $8,930
Dr. Kenneth Mauer, Md, MD
Specialist — Payments: $6,373
Specialist $6,373